Estudios
I+D+I
Institución
Internacional
Vida Universitaria
Atlantis Institut des Sciences Fictives
Recherche
Soumettre
Personnaliser
Vos alertes
Vos paniers
Vos recherches
Aide
EN
/
ES
Accueil
>
articulos
> The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies
Statistiques d'utilisation
Graphiques
The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies
Butnariu, M.
;
Quispe, C.
;
Herrera-Bravo, J.
;
Helon, P.
;
Kukula-Koch, W.
;
López Ramos, V.
;
Les, F.
;
Vergara, C. V.
;
Alarcón-Zapata, P.
;
Alarcón-Zapata, B.
;
Martorell, M.
;
Pentea, M.
;
Dragunescu, A. A.
;
Samfira, I.
;
Yessimsiitova, Z.
;
Dastan, S. D.
;
Castillo, C. M. S.
;
Roberts, T. H.
;
Sharifi-Rad, J.
;
Koch, W.
;
Cho, W. C.
Resumen:
Thymoquinone (TQ) is a secondary metabolite found in abundance in very few plant species including Nigella sativa L., Monarda fistulosa L., Thymus vulgaris L. and Satureja montana L. Preclinical pharmacological studies have shown that TQ has many biological activities, such as anti-inflammatory, antioxidant and anticancer. Both in vivo and in vitro experiments have shown that TQ acts as an antitumor agent by altering cell cycle progression, inhibiting cell proliferation, stimulating apoptosis, inhibiting angiogenesis, reducing metastasis and affecting autophagy. In this comprehensive study, the evidence on the pharmacological potential of TQ on pancreatic cancer is reviewed. The positive results of preclinical studies support the view that TQ can be considered as an additional therapeutic agent against pancreatic cancer. The possibilities of success for this compound in human medicine should be further explored through clinical trials. © 2022 The Authors
Idioma:
Inglés
DOI:
10.1016/j.biopha.2022.113364
Año:
2022
Publicado en:
BIOMEDICINE & PHARMACOTHERAPY
153 (2022), 113364 [10 pp]
ISSN:
0753-3322
Factor impacto JCR:
7.5 (2022)
Categ. JCR:
PHARMACOLOGY & PHARMACY
rank: 22 / 278 = 0.079
(2022)
- Q1
- T1
Categ. JCR:
MEDICINE, RESEARCH & EXPERIMENTAL
rank: 27 / 136 = 0.199
(2022)
- Q1
- T1
Factor impacto CITESCORE:
12.6 -
Pharmacology, Toxicology and Pharmaceutics
(Q1) -
Medicine
(Q1)
Factor impacto SCIMAGO:
1.366 -
Pharmacology
(Q1) -
Medicine (miscellaneous)
(Q1)
Tipo y forma:
Article (Published version)
Exportado de SIDERAL (2024-03-18-14:40:53)
Permalink:
Copy
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
articulos
Retour à la recherche
Notice créée le 2022-10-06, modifiée le 2024-03-19
Versión publicada:
PDF
Évaluer ce document:
Rate this document:
1
2
3
4
5
(Pas encore évalué)
Ajouter au panier personnel
Exporter vers
BibTeX
,
MARC
,
MARCXML
,
DC
,
EndNote
,
NLM
,
RefWorks